Abstract：
UNASSIGNED: Major depressive disorder (MDD) is a prevalent, chronic disorder. Auvelity (dextromethorphan-bupropion) is a novel, oral N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist approved (August 2022) by the FDA for treating MDD in adults. This is the first analysis on real-world Auvelity usage in the United States.
UNASSIGNED: Adult patients initiating Auvelity in the Symphony IDV databases by September 2023 were identified (index date: the first Auvelity claim). Patients had continuous eligibility over the 12-month pre-index period and ≥1 MDD diagnosis (ICD-10-CM codes: F32.*, F33.*) over the 5-year pre-index period. Demographic and clinical characteristics, comorbidities, prior MDD-related medications, and Auvelity initiation status were assessed.
UNASSIGNED: This analysis included 22,288 patients with MDD treated with Auvelity (mean age 45.1 years; 68.1% women); 40.0% lived in the South and 58.5% had commercial insurance. Comorbidities included mental health disorders (53.5%; 47.6% had anxiety disorders). Overall, 83.7% of the patients had received treatment with selective serotonin reuptake inhibitors (SSRIs; 54.9%), the norepinephrine-dopamine reuptake inhibitor (NDRI [bupropion]; 40.4%), and/or serotonin-norepinephrine reuptake inhibitors (SNRIs; 35.9%) over the 12-month pre-index period. The last MDD-related treatment prior to Auvelity comprised SSRI (22.4%), SNRI (13.2%), and NDRI (12.8%) monotherapies; 294 (1.3%) patients received esketamine. In total, 6,418 (28.8%) patients initiated Auvelity as monotherapy vs 15,870 (71.2%) as an add-on; Auvelity was most frequently added to an SSRI alone (10.7%) or SNRI alone (6.5%). A total of 2,254 (10.1%) patients initiated Auvelity without prior treatment in the 12-month pre-index period.
UNASSIGNED: Incomplete data due to reporting; diagnoses captured subject to coding error; and limited generalizability to other populations.
UNASSIGNED: Using a large demographically distributed claims database, 22,288 patients with MDD initiated Auvelity within a year of its approval; 10.1% were treatment-naïve and 28.8% initiated Auvelity as monotherapy. Most patients had mental health-related comorbidities and attempted various MDD-related treatments prior to Auvelity.
Major depressive disorder (medical terminology for “depression”) is a common medical condition that makes people feel persistently sad or hopeless, affecting their ability to handle daily activities. Effective treatment, which may include medication, is crucial for improving their quality of life. This study explores how people in the United States use a new medication called Auvelity to treat depression. Researchers reviewed the medical records of over 22,000 adults with depression, looking at their age, gender, location, type of health insurance, other health conditions, and use of other depression medications. The study focused on people who started using Auvelity in the first year after its Food and Drug Administration (FDA) approval. On average, Auvelity users were 45 years old. They lived across various regions of the US, had different types of health insurance, and over two-thirds were women. Many Auvelity users had other mental health disorders, including anxiety. Most had tried different types of medications for depression in the previous year, while about 10% had not used any other depression medicines in the previous year. When starting Auvelity, almost one-third of patients used it as their only depression medicine. Over two-thirds of patients started Auvelity alongside another depression medicine. Initial Auvelity prescriptions were issued by a diverse range of medical professionals, including psychiatrists, primary care physicians, nurse practitioners, and physician assistants. These findings provide valuable insights into how this new medicine is used in real life and can inform treatment decisions of healthcare providers who help manage depression in their patients.
UNASSIGNED: Adult patients initiating Auvelity in the Symphony IDV databases by September 2023 were identified (index date: the first Auvelity claim). Patients had continuous eligibility over the 12-month pre-index period and ≥1 MDD diagnosis (ICD-10-CM codes: F32.*, F33.*) over the 5-year pre-index period. Demographic and clinical characteristics, comorbidities, prior MDD-related medications, and Auvelity initiation status were assessed.
UNASSIGNED: This analysis included 22,288 patients with MDD treated with Auvelity (mean age 45.1 years; 68.1% women); 40.0% lived in the South and 58.5% had commercial insurance. Comorbidities included mental health disorders (53.5%; 47.6% had anxiety disorders). Overall, 83.7% of the patients had received treatment with selective serotonin reuptake inhibitors (SSRIs; 54.9%), the norepinephrine-dopamine reuptake inhibitor (NDRI [bupropion]; 40.4%), and/or serotonin-norepinephrine reuptake inhibitors (SNRIs; 35.9%) over the 12-month pre-index period. The last MDD-related treatment prior to Auvelity comprised SSRI (22.4%), SNRI (13.2%), and NDRI (12.8%) monotherapies; 294 (1.3%) patients received esketamine. In total, 6,418 (28.8%) patients initiated Auvelity as monotherapy vs 15,870 (71.2%) as an add-on; Auvelity was most frequently added to an SSRI alone (10.7%) or SNRI alone (6.5%). A total of 2,254 (10.1%) patients initiated Auvelity without prior treatment in the 12-month pre-index period.
UNASSIGNED: Incomplete data due to reporting; diagnoses captured subject to coding error; and limited generalizability to other populations.
UNASSIGNED: Using a large demographically distributed claims database, 22,288 patients with MDD initiated Auvelity within a year of its approval; 10.1% were treatment-naïve and 28.8% initiated Auvelity as monotherapy. Most patients had mental health-related comorbidities and attempted various MDD-related treatments prior to Auvelity.
Major depressive disorder (medical terminology for “depression”) is a common medical condition that makes people feel persistently sad or hopeless, affecting their ability to handle daily activities. Effective treatment, which may include medication, is crucial for improving their quality of life. This study explores how people in the United States use a new medication called Auvelity to treat depression. Researchers reviewed the medical records of over 22,000 adults with depression, looking at their age, gender, location, type of health insurance, other health conditions, and use of other depression medications. The study focused on people who started using Auvelity in the first year after its Food and Drug Administration (FDA) approval. On average, Auvelity users were 45 years old. They lived across various regions of the US, had different types of health insurance, and over two-thirds were women. Many Auvelity users had other mental health disorders, including anxiety. Most had tried different types of medications for depression in the previous year, while about 10% had not used any other depression medicines in the previous year. When starting Auvelity, almost one-third of patients used it as their only depression medicine. Over two-thirds of patients started Auvelity alongside another depression medicine. Initial Auvelity prescriptions were issued by a diverse range of medical professionals, including psychiatrists, primary care physicians, nurse practitioners, and physician assistants. These findings provide valuable insights into how this new medicine is used in real life and can inform treatment decisions of healthcare providers who help manage depression in their patients.
摘要：
目的：重度抑郁症(MDD)是一种普遍存在的疾病，慢性疾病。Auvelity®（右美沙芬-安非他酮）是一种新颖的，口服,FDA批准的N-甲基-D-天冬氨酸（NMDA）受体拮抗剂和sigma-1受体激动剂（2022年8月）用于治疗成人MDD。这是对美国现实世界中Auvelity使用情况的首次分析。方法：到2023年9月在SymphonyIDV®数据库中启动Auvelity的成年患者被确定（索引日期：第一次Auvelity索赔）。患者在12个月的预索引期内具有连续资格，并且≥1个MDD诊断（ICD-10-CM代码：F32。*,F33.*)在5年的预指数期间。人口统计学和临床特征，合并症,以前的MDD相关药物，和Auvelity启动状态进行了评估。结果：该分析包括22,288例接受Auvelity治疗的MDD患者（平均年龄45.1岁；68.1％的女性）；40.0％居住在南方，58.5％拥有商业保险。合并症包括心理健康障碍（53.5％；47.6％患有焦虑症）。总的来说,83.7%的患者接受过选择性5-羟色胺再摄取抑制剂治疗(SSRIs;54.9%),去甲肾上腺素-多巴胺再摄取抑制剂（NDRI[安非他酮];40.4%），和/或5-羟色胺-去甲肾上腺素再摄取抑制剂(SNRIs;35.9%)在12个月的预指数期间。Auvelity之前的最后一次MDD相关治疗包括SSRIs（22.4%），SNRI（13.2%），和NDRI（12.8％）单一疗法;294（1.3％）患者接受了艾氯胺酮。总的来说,6,418名患者（28.8％）作为单一疗法开始了Auvelity，而15,870名（71.2％）作为附加疗法；Auvelity最常添加到单独的SSRI（10.7％）或单独的SNRI（6.5％）中。在12个月的索引前期间，共有2,254名（10.1％）患者在没有事先治疗的情况下开始了Auvelity。局限性：由于报告导致的数据不完整；编码错误捕获的诊断；对其他人群的普适性有限。结论：使用大型人口分布的索赔数据库，22,288例MDD患者在批准后的一年内开始使用Auvelity；10.1％的患者初治，28.8％的患者开始使用Auvelity作为单一疗法。大多数患者患有与心理健康相关的合并症，并在Auvelity之前尝试了各种与MDD相关的治疗。
重度抑郁症（医学术语“抑郁症”）是一种常见的医疗状况，使人们持续感到悲伤或绝望，影响他们处理日常活动的能力。有效治疗,其中可能包括药物，对提高他们的生活质量至关重要。这项研究探讨了美国人如何使用一种名为Auvelity®的新药来治疗抑郁症。研究人员回顾了超过22,000名患有抑郁症的成年人的医疗记录，看看他们的年龄,性别,location,健康保险的类型，其他健康状况,和使用其他抑郁症药物。该研究的重点是在食品和药物管理局（FDA）批准后的第一年开始使用Auvelity的人。平均而言,Auvelity用户45岁。他们生活在美国的不同地区，有不同类型的医疗保险，超过三分之二是女性。许多Auvelity用户有其他心理健康障碍，包括焦虑。大多数人在前一年尝试了不同类型的抑郁症药物，而大约10%的人在前一年没有使用任何其他抑郁症药物。当开始Auvelity时,几乎三分之一的患者使用它作为他们唯一的抑郁症药物。超过三分之二的患者与另一种抑郁症药物一起服用了Auvelity。最初的Auvelity处方是由各种各样的医疗专业人员签发的，包括精神病医生,初级保健医生，执业护士,和医生助理。这些发现为如何在现实生活中使用这种新药提供了有价值的见解，并可以为帮助管理患者抑郁症的医疗保健提供者提供治疗决策。
重度抑郁症（医学术语“抑郁症”）是一种常见的医疗状况，使人们持续感到悲伤或绝望，影响他们处理日常活动的能力。有效治疗,其中可能包括药物，对提高他们的生活质量至关重要。这项研究探讨了美国人如何使用一种名为Auvelity®的新药来治疗抑郁症。研究人员回顾了超过22,000名患有抑郁症的成年人的医疗记录，看看他们的年龄,性别,location,健康保险的类型，其他健康状况,和使用其他抑郁症药物。该研究的重点是在食品和药物管理局（FDA）批准后的第一年开始使用Auvelity的人。平均而言,Auvelity用户45岁。他们生活在美国的不同地区，有不同类型的医疗保险，超过三分之二是女性。许多Auvelity用户有其他心理健康障碍，包括焦虑。大多数人在前一年尝试了不同类型的抑郁症药物，而大约10%的人在前一年没有使用任何其他抑郁症药物。当开始Auvelity时,几乎三分之一的患者使用它作为他们唯一的抑郁症药物。超过三分之二的患者与另一种抑郁症药物一起服用了Auvelity。最初的Auvelity处方是由各种各样的医疗专业人员签发的，包括精神病医生,初级保健医生，执业护士,和医生助理。这些发现为如何在现实生活中使用这种新药提供了有价值的见解，并可以为帮助管理患者抑郁症的医疗保健提供者提供治疗决策。
